COVID-19 has exposed many weaknesses in pandemic preparedness, not least when it comes to active pharmaceutical ingredients, and Carl-Åke Carlsson CEO of API and FDF manufacturer Xellia Pharmaceuticals Aps is clear about what needs to be done.
“I think both the US and Europe have become very reliant on countries outside the US and the EU,” said Carlsson, as he pointed out that a lot of active pharmaceutical ingredients and critical intermediaries come from China and India
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?